Remicade (infliximab) denied due to quantity / dose limits by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare Limits Infliximab (Remicade) Quantities — and Why You Can Appeal

UnitedHealthcare applies quantity or frequency limits to infliximab infusions based on its internal coverage policy, which defines the number of infusions, dosing intervals, and weight-based administration protocols it will authorize within a given period. When a prescriber orders an infusion schedule that falls outside those parameters — because of disease activity, body weight, or a clinically supported dose escalation — UHC may deny the additional quantities as exceeding its limit.

This denial is appealable. The quantity limit in UHC's policy must be consistent with the FDA-approved prescribing label for infliximab, which itself provides a dosing range and escalation pathway for inadequate response. If your physician has ordered a schedule that is within the label's approved range, UHC cannot simply substitute its own lower limit without medical justification. Courts and external reviewers have repeatedly found that formulary quantity restrictions cannot conflict with the labeled indication.

## The Federal Appeal Framework

• Internal appeal (Level 1): File within 180 days of the denial. UHC must decide within 30 days (pre-service) or 60 days (post-service).
• External review: After exhausting internal appeals — or after 72 hours with no urgent-care decision — you may request independent external review under ACA §2719. The reviewer is bound by the terms of your plan but applies clinical evidence, not just UHC policy. The window to request external review is typically 4 months from the final internal denial.
• ERISA §503: If your plan is employer-sponsored, you are entitled to a full-and-fair review with access to the specific criteria used in the denial.
• Expedited track: For ongoing infusions where a gap would cause clinical harm, request expedited review — UHC must respond within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Specialist notes confirming the underlying condition (Crohn's disease, ulcerative colitis, rheumatoid arthritis, etc.) and current disease activity level.
• Prescribing rationale: A medical-necessity letter from your infusion prescriber explaining why the ordered schedule — dose, interval, or weight-based adjustment — is within the FDA-approved label and clinically required.
• Prior treatment history: Dated records of earlier therapies tried, response, and reason for any dose modifications.
• Lab and clinical severity data: Recent labs, endoscopy findings, or disease-activity scores that document the clinical picture supporting the ordered regimen.
• The FDA-approved prescribing information: Obtain the current label from DailyMed (dailymed.nlm.nih.gov) and highlight the dose range and escalation language that covers your ordered schedule.

## Criteria-Mapping Strategy

Request UHC's published Coverage Determination Guideline for infliximab. List every criterion it states for quantity authorization. For each criterion, identify the corresponding chart entry — a lab result, physician note, or procedure report — that satisfies it. Present this as a side-by-side table in your appeal letter. Explicitly cross-reference the FDA label to show your ordered quantity falls within approved parameters. If UHC's limit is more restrictive than the label without clinical support, state that directly and cite the ACA anti-discrimination standard for coverage of approved treatments.